SLC5A2 and COVID-19: Recent data showed that metformin, the first-line treatment for type 2 diabetes, was associated with significantly reduced mortality in patients with COVID-19.[29,30] SGLT-2 treatment was not recommended according to some studies due to the risk of ketoacidosis and dehydration[23,24] albeit in a recent study performed in hospitalized COVID-19 patients with and without diabetes, dapagliflozin treatment was well tolerated, and no side effects were reported.[21]